TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN
TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN Basic information
- Product Name:
- TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN
- Synonyms:
-
- H-TYR-GLY-SER-LEU-PRO-GLN-LYS-ALA-GLN-ARG-PRO-GLN-ASP-GLU-ASN-OH
- H-TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN-OH
- (DES-GLY77,DES-HIS78)-MYELIN BASIC PROTEIN (68-84) (BOVINE)
- (DES-GLY77,DES-HIS78)-MYELIN BASIC PROTEIN (68-84) (GUINEA PIG)
- DES-GLY77, DES-HIS78-MYELIN BASIC PROTEIN FRAGMENT 68-84 BOVINE
- DES-[GLY77,HIS78] MYELIN BASIC PROTEIN (68-84), BOVINE
- DES[GLY77,HIS78]-MYELIN BASIC PROTEIN, FRAGMENT 68-64
- DES[GLY77, HIS78]-SER75,80-MYELIN BASIC PROTEIN BOVINE FRAGMENT 68-84
- CAS:
- 98474-59-0
- MF:
- C71H113N23O28
- MW:
- 1736.81
- Product Categories:
-
- Peptide
- Neuroscience
- Mol File:
- 98474-59-0.mol
TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN Chemical Properties
- storage temp.
- -20°C
- solubility
- insoluble in EtOH; ≥173.6 mg/mL in DMSO; ≥54.6 mg/mL in H2O
- form
- solid
- color
- White to off-white
- biological source
- guinea pig
- Sequence
- H-Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn-OH
MSDS
- Language:English Provider:SigmaAldrich
TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN Usage And Synthesis
Uses
Myelin Basic Protein Guinea Pig Fragment 68-82 has been used for lymphocyte activation in human blood samples. It has also been used as a component of the incomplete Freundμs adjuvant for the induction of autoimmune encephalomyelitis in rats.
Biological Activity
myelin basic protein (68-82), guinea pig,(c71h113n23o28) is a peptide with the sequence tyr-gly-ser-leu-pro-gln-lys-ser-gln-arg-ser-gln-asp-glu-asn, mw= 1736.79. myelin basic protein (mbp) is a protein believed to be important in the process of myelination of nerves in the nervous system. knockout mice deficient in mbp showed decreased amounts of cns myelination and have developed a progressive disorder characterized by tremors, seizures, and early death. mbp research has centered on its role in demyelinating diseases, in particular, multiple sclerosis (ms). several studies have uncovered the role of antibodies against mbp in the pathogenesis of ms.] some studies have linked a genetic predisposition to ms to the mbp gene, though a majority have not. some recent work has shown that inoculating an animal with mbp to generate an immune response against it increases blood–brain barrier permeability.figure1 formula of myelin basic protein (68-82), guinea pigfigure2 structure of myelin basic protein
Biochem/physiol Actions
Myelin basic protein fragment that induces experimental allergic encephalomyelitis.
in vivo
Whether pretreatment with bee venom acupuncture (BVA) from the same day of MBP (68-82) immunization can affect the induction and progression of experimental autoimmune encephalomyelitis (EAE) and weight loss is examined. At 5-9 days after immunization, rats in the myelin basic protein (MBP) group start displaying partial loss of tail tonus (clinical signs, 0.5) in a freely moving environment. At 10-16 days after immunization, most of the rats in the MBP group display more severe symptoms of neurological deficit including paraparesis of the hindlimb, paraplegia, tetraparesis, and tetraplegia. In contrast, rats in the MBP?+?BVA group display relatively slight neurological deficits in a dose-dependent manner at 11-15 days after immunization, compared to the rats in the MBP group. The onset of symptoms is slightly delayed (BVA 0.8 mg/kg, 6.4±0.6 days) and the maximal clinical score is markedly decreased (BVA 0.25 mg/kg, 3.7±0.2; BVA 0.8 mg/kg, 2.8±0.3), compared to that in the MBP group. At this time, the mean body weight of rats in the MBP group is decreased as compared to that of rats in the normal group, but it is significantly increased in rats of the MBP?+?BVA group as compared to rats in the MBP group[2].
References
1. Sakamoto Y, Kitamura K, Yoshimura K, Nishijima T, Uyemura K (March 1987). "Complete amino acid sequence of POprotein in bovine peripheral nerve myelin". J. Biol. Chem. 262 (9): 4208–14.2. Deber CM, Reynolds SJ (April 1991). "Central nervous system myelin: structure, function, and pathology". Clin. Biochem. 24 (2): 113–34.3. Inouye H, Kirschner DA (January 1991). "Folding and function of the myelin proteins from primary sequence data". J. Neurosci. Res. 28 (1): 1–17.4. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (July 2003). "Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event". N. Engl. J. Med. 349 (2): 139–45.
TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASNSupplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0551-65326643 18156095617
- info@cellmano.com
- Tel
- +1-832-696-8203
- info@apexbt.com